PhoreMost Signs a Multi-Project Drug Discovery Agreement with Boehringer Ingelheim
Boehringer Ingelheim Signs a Clinical Research Agreement with Amal for the Evaluation of Combination Therapy to Treat Stage IV Colorectal Cancer
Shots:
- PhoreMost to receive upfront and research funding plus milestones and will utilize its expertise and phenotypic screening platform, SITESEEKER for the targets identified by BI and will be further included in and validated in BI’s pipeline
- The focus of the agreement is to enhance BI’s drug discovery pipeline utilizing PhoreMost’s PROTEINi and SITESEEKER platform to identify novel targets for multiple diseases
- SITESEEKER platform is based on PROTEINi technology enables the inception of novel drug discovery programs. PROTEINi are small fragments of larger proteins broken into small subunits retaining a 3D structure find a diversity of new 3D binding sites across the entire proteome
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Behance